Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
SUBSCRIBE
Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
Global Market Bulletin
No Result
View All Result
Home Stock Market News

Helport AI (HPAI) Revenue Soars 132% in FY 2024 Following Nasdaq Debut

by Global Market Bulletin
November 6, 2024
in Stock Market News
0
Helport AI (HPAI) Revenue Soars 132% in FY 2024 Following Nasdaq Debut

Crown ElectroKinetics (CRKN): $8M Q3 Revenue Signals Rapid Growth in 2024

19
SHARES
41
VIEWS
Share on FacebookShare on Twitter

Helport AI Limited (HPAI), an emerging leader in AI-powered enterprise solutions, released its fiscal year 2024 financial results, showcasing substantial growth in revenue and profitability.

You might also like

Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

Helport, recently listed on Nasdaq, saw a 132% revenue increase to $29.6 million for FY 2024. The company is a global AI technology provider delivering scalable software and services designed to enhance customer engagement across industries.

With a commitment to operational excellence and innovation, Helport’s solutions empower businesses to optimize customer interactions, driving sustainable growth.

Helport AI (HPAI) Revenue Soars 132% in FY 2024 Following Nasdaq Debut

CHECK THIS OUT: Gilat (GILT) Wins $4M U.S. Defense Contract for Transportable Satellite Hubs

Strong Financial Results Driven by Growing Market Demand

Helport AI’s fiscal year 2024 marked notable milestones, as revenue climbed from $12.7 million in the prior year to $29.6 million, reflecting its expanding client base and market reach.

The company reported a 53% increase in net income, reaching $7.4 million, showcasing strong market positioning. Gross profit surged 137% to $18.6 million, with gross margin rising to 62.8% due to cost optimization.

CEO Guanghai Li credited this growth to Helport’s strengthened market presence, strategic partnerships, and Nasdaq listing.

“Our Nasdaq debut is a major achievement that boosts our visibility and credibility, especially in the U.S. market,” Li stated.

“As we continue to develop and enhance our AI solutions, we expect this momentum to extend into 2025, supporting our expansion efforts and bolstering our product offerings.”

Expansion of AI Product Line and Global Presence

Helport AI is intensifying its focus on AI-powered solutions designed to transform customer engagement. Its flagship product, Helport AI Assist, has gained traction in the enterprise market, with key applications in sales guidance, quality assurance, and real-time communication.

The platform’s recent listing on Google Cloud Marketplace signals Helport’s dedication to improving the accessibility and integration of its tools, particularly for North American clients.

The company’s AI+BPO service offers 24/7 multilingual support, an advantage for industries such as banking, insurance, and government services. With offices in Singapore and San Diego, Helport is positioned for global growth, supported by partnerships with organizations like Google and eWorld Enterprise Solutions.

Innovating for the Future with Helport AI Developer Ecosystem (HDE)

Helport AI plans to launch the Helport AI Developer Ecosystem (HDE), an open API platform for developers. This strategic initiative aims to foster innovation, attracting developers across sectors to leverage Helport’s AI capabilities.

Additionally, the company projects strong growth for fiscal 2025, fueled by strategic partnerships, rising AI demand, and Nasdaq momentum. Helport’s upcoming HDE launch and U.S. expansion are set to drive innovation and strengthen its AI enterprise solutions.

READ ALSO: Treace Medical (TMCI) Reports $44.5M Q2 Revenue, 6% Growth in Q2 2024 and Spirit Airlines in Q2 2024: $1.28B Revenue, Plus New Travel Options.

Tags: Helport AI Limited (HPAI)
Share8Tweet5

Global Market Bulletin

Global Market Bulletin is a leading provider of stock market updates, economic news, and personalized investing guides. Our team brings you the latest global financial information to help you make smart investment decisions. About the Editorial Team Our editorial team consists of financial experts and seasoned market analysts who bring decades of experience to our coverage. With a commitment to unbiased reporting, our team ensures that every article is backed by thorough research and delivers accurate financial insights.

Recommended For You

Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

by Global Market Bulletin
July 18, 2026
0
Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

by Global Market Bulletin
July 18, 2026
0
Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

by Global Market Bulletin
July 18, 2026
0
Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

What Makes SharpLink (SBET) a High-Risk Stock Investors Cannot Ignore?

by Global Market Bulletin
July 18, 2026
0
What Makes SharpLink (SBET) a High-Risk Stock Investors Cannot Ignore?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Omeros (OMER) a Smart Biotech Investment Before Its Next Major Catalyst?

by Global Market Bulletin
July 18, 2026
0
Is Omeros (OMER) a Smart Biotech Investment Before Its Next Major Catalyst?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Browse by Category

  • CEO Interviews
  • Economy
  • Investing
  • Stock Market News
  • Uncategorized

QUICK LINKS

  • Stock Market News
  • Investing
  • Economy
  • Contact Us
  • About Global Market Bulletin
  • Editorial Policy – Global Market Bulletin
  • Our Editorial Team

RECENT POSTS

  • Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?
  • Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?
  • Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

GET EMAIL MARKET UPDATES

Subscribe to our mailing list to receives daily updates direct to your inbox!
  • Privacy Policy
  • Terms and Conditions

© 2022 Global Market Bulletin. All Rights Reserved.

No Result
View All Result
  • Home
  • Stock Market News
  • Investing
  • Economy

© 2022 Global Market Bulletin. All Rights Reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?